Market LIVE
Published markets; coverage varies by country
Product profile · United States

NUCYNTA

 ·  Patent Litigation & Settlement History ↓

IngredientTAPENTADOL HYDROCHLORIDE
Application typeNDA
Application203794
Product001
Dosage formSOLUTION
RouteORAL
StrengthEQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval date2012-10-15
Marketing statusDiscontinued
Status event—
ApplicantCOLLEGIUM PHARM INC
Product source

Current GenericRadar decision

Year2026
SelectionDISQUALIFIED
ReviewFINAL
Anchor typeEXISTING_GENERIC
Anchor date2026-01-26
Patent anchor—
Exclusivity anchor—
Protection date2027-01-03
First Final ANDA2026-01-26
Status event—

Exact ingredient/form/route/strength Final ANDA 219119 exists. Authorized generics, tentative approvals and commercial launch dates are excluded.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NPP—2026-07-03New patient population; not automatically full label.NN——Source
NPP2023-07-032026-07-03New patient population; not automatically full label.NN——Source
PED—2027-01-03Six-month attachment to the specified base patent or exclusivity; not a standalone award.NN——Source
PED2026-07-032027-01-03Six-month attachment to the specified base patent or exclusivity; not a standalone award.NN——Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (3)
TypeDateRoleBasisSource
REGULATORY_EXCLUSIVITY—SCOPE_CONTEXTNew patient population; not automatically full label.Source
REGULATORY_EXCLUSIVITY—SCOPE_CONTEXTSix-month attachment to the specified base patent or exclusivity; not a standalone award.Source
REGULATORY_STATUS—TERMINAL_STATUSExact ingredient/form/route/strength Final ANDA 219119 exists. Authorized generics, tentative approvals and commercial launch dates are excluded.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.